改善心力衰竭护理的新机会:专注于皮下注射的西米德
Wahab J Khan1, Jose Arriola-Montenegro2, Melinda S Mutschler2
1Department of Medicine, Avera Health, Sioux Falls, SD, 57105, USA.
Heart failure reviews
|July 13, 2023
概括
无pH值的富洛塞米德提供了一种新的方法,可以在家中管理心力衰竭 (HF) 拥堵. 这种皮下治疗可以减少住院,改善患者的生活质量,降低医疗保健成本.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 全球心力衰竭 (HF) 的患病率正在增加.
- 症状性拥堵是HF住院的主要驱动因素.
- 目前的管理往往需要在医院环境下静脉注射利尿剂.
研究的目的:
- 审查pH中性的furosemide的药理学和药理动力学.
- 总结一下临床试验数据,以家庭为基础的皮下furosemide治疗.
- 评估这种新型治疗方法在去补偿性心力衰竭管理中的潜力.
主要方法:
- 关于pH中性富洛塞米德的现有文献的综述.
- 对临床试验数据的分析,以确定家庭使用的疗效.
- 药理动力学和药理动力学分析.
主要成果:
- 在pH中立的furosemide中,它显示了皮下输送的良好特征.
- 临床试验表明,在家庭环境中控制拥堵是有效的.
- 该疗法已获得FDA批准用于失补偿性心力衰竭.
结论:
- 皮下pH中性furosemide有可能将脱血疗法从医院转移到家庭环境中.
- 这种方法可以显著改善心力衰竭患者的生活质量.
- 预计这将减少与HF入院相关的医疗保健支出.
相关概念视频
Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
Heart Failure Drugs: Diuretics
424
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
424
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inotropic Agents
633
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
633
Heart Failure VII: Nursing Interventions
99
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
99
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465


